Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLXNASDAQ:PBYINASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$6.33-2.6%$5.17$1.62▼$7.27$564.26M-0.591.19 million shs11.94 million shsPBYIPuma Biotechnology$3.33+0.6%$3.27$2.23▼$4.13$165.27M1.29417,329 shs699,742 shsSAVACassava Sciences$1.75-4.4%$1.91$1.15▼$42.20$84.54M-22.98 million shs5.99 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals0.00%+25.35%+21.03%+78.81%+233.16%PBYIPuma Biotechnology0.00%+4.39%0.00%+12.50%+2.15%SAVACassava Sciences0.00%-12.06%-13.79%+16.67%-85.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLXAmylyx Pharmaceuticals3.6716 of 5 stars4.52.00.00.02.53.30.6PBYIPuma Biotechnology4.2522 of 5 stars3.52.00.00.02.64.23.1SAVACassava Sciences4.2806 of 5 stars3.33.00.04.73.40.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.92Moderate Buy$11.0073.78% UpsidePBYIPuma Biotechnology 3.00Buy$7.00110.21% UpsideSAVACassava Sciences 2.50Moderate Buy$54.503,014.29% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, PBYI, and SAVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025AMLXAmylyx PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold6/24/2025AMLXAmylyx PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold6/24/2025AMLXAmylyx PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.006/17/2025AMLXAmylyx PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.005/30/2025AMLXAmylyx PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/14/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.005/9/2025AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $16.005/7/2025AMLXAmylyx PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $10.005/6/2025AMLXAmylyx PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/7/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$3.00 ➝ $7.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M6.46N/AN/A$2.40 per share2.64PBYIPuma Biotechnology$230.50M0.72$0.85 per share3.91$1.88 per share1.77SAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$301.74M-$3.11N/AN/AN/AN/A-77.21%-63.84%8/6/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.774.328.76N/A16.37%49.35%18.25%7/30/2025 (Estimated)SAVACassava Sciences-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/6/2025 (Estimated)Latest AMLX, PBYI, and SAVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.45-$0.42+$0.03-$0.42N/AN/A5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A12.0512.05PBYIPuma Biotechnology0.111.531.43SAVACassava SciencesN/A9.089.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%PBYIPuma Biotechnology61.29%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals11.70%PBYIPuma Biotechnology23.30%SAVACassava Sciences12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.14 million78.71 millionOptionablePBYIPuma Biotechnology20049.63 million38.07 millionOptionableSAVACassava Sciences3048.31 million42.41 millionOptionableAMLX, PBYI, and SAVA HeadlinesRecent News About These CompaniesSAVA Stock Price for Cassava Sciences Inc - MorningstarJune 28 at 11:21 PM | morningstar.comMWhy cassava could be a great addition to a balanced dietJune 26, 2025 | msn.comTwo Sigma Investments LP Has $1.33 Million Position in Cassava Sciences, Inc. (NASDAQ:SAVA)June 5, 2025 | marketbeat.comTwo Sigma Advisers LP Invests $1.43 Million in Cassava Sciences, Inc. (NASDAQ:SAVA)June 1, 2025 | marketbeat.comCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava partners with Zindi to give African AI developers better toolsMay 15, 2025 | techzim.co.zwTCassava Sciences Inc.May 15, 2025 | barrons.com5 ON YOUR SIDE: Lead levels in cassava flourMay 15, 2025 | kstp.comKCassava Technologies, Zindi collaborate on AI servicesMay 12, 2025 | msn.comCassava Technologies and Zindi collaborate to showcase African A.I. innovationMay 12, 2025 | thezimbabwemail.comTCassava Technologies and Zindi Partner to Supercharge Africa’s AI and GPU EcosystemMay 12, 2025 | devdiscourse.comDNew report finds concerning levels of lead in popular cassava itemsMay 12, 2025 | yahoo.comCassava takes next step for African AIMay 12, 2025 | htxt.co.zaHCassava Technologies and Zindi collaborate to showcase African Artificial Intelligence (AI) innovationMay 12, 2025 | zawya.comZCassava Reports Q1 2025 Financials Results, Provides Business UpdateMay 9, 2025 | finance.yahoo.comZindi Teams Up with Cassava to Spotlight African AI TalentMay 6, 2025 | msn.comZindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovationMay 5, 2025 | msn.comCassava Consciousness from The Tamarind Galaxy part twoMay 1, 2025 | modernghana.comMCassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSCMay 1, 2025 | globenewswire.comTargeted and random mutagenesis of cassava brown streak disease susceptibility factors reveal molecular determinants of disease severityApril 30, 2025 | elifesciences.orgENew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMLX, PBYI, and SAVA Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$6.33 -0.17 (-2.62%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$6.32 -0.01 (-0.24%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Puma Biotechnology NASDAQ:PBYI$3.33 +0.02 (+0.60%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.40 +0.07 (+2.25%) As of 06/27/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Cassava Sciences NASDAQ:SAVA$1.75 -0.08 (-4.37%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.80 +0.05 (+2.86%) As of 06/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
